On August 28, 2024 Medigene AG (Medigene or the "Company", FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, reported that it will be presenting at the the annual German Fall Conference to be held in Frankfurt from September 2-3, 2024 as well as at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024 in New York and at the Baader Investment Conference from September 23-26, 2024 in Munich (Press release, MediGene, AUG 28, 2024, View Source [SID1234646166]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Corporate presentation – German Fall Conference 2024
View Source
Location: Le Meridien Hotel Frankfurt, Frankfurt, Germany
Date and time: Monday, September 2, 2024, 10 am – 10.40 am local time
Speaker: Dr. Selwyn Ho, CEO

Corporate presentation – H.C. Wainwright 26th Annual Global Investment Conference 2024
View Source
Location: Lotte New York Palace, New York, USA
Date and time: to be determined
Speaker: James Cornicelli, Senior Vice President, Head of Corporate Development & Strategy

Corporate presentation – Baader Investment Conference 2024
View Source
Location: Hotel Sofitel Munich Bayerpost, Munich, Germany
Date and time: Wednesday, September 25, 2024, 12.30 pm – 1.10pm local time, panel room 3
Speaker: Dr. Selwyn Ho, CEO

Members of Medigene’s management team will be available for one-on-one meetings with registered investors at the events.